292 related articles for article (PubMed ID: 17399734)
1. Canine subcutaneous mast cell tumour: diagnosis and prognosis.
Newman SJ; Mrkonjich L; Walker KK; Rohrbach BW
J Comp Pathol; 2007 May; 136(4):231-9. PubMed ID: 17399734
[TBL] [Abstract][Full Text] [Related]
2. Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication.
Webster JD; Yuzbasiyan-Gurkan V; Miller RA; Kaneene JB; Kiupel M
Vet Pathol; 2007 May; 44(3):298-308. PubMed ID: 17491070
[TBL] [Abstract][Full Text] [Related]
3. Association of argyrophilic nucleolar organizing regions, Ki-67, and proliferating cell nuclear antigen scores with histologic grade and survival in dogs with soft tissue sarcomas: 60 cases (1996-2002).
Ettinger SN; Scase TJ; Oberthaler KT; Craft DM; McKnight JA; Leibman NF; Charney SC; Bergman PJ
J Am Vet Med Assoc; 2006 Apr; 228(7):1053-62. PubMed ID: 16579784
[TBL] [Abstract][Full Text] [Related]
4. Association of Ki67 index with prognosis for intermediate-grade canine cutaneous mast cell tumours.
Maglennon GA; Murphy S; Adams V; Miller J; Smith K; Blunden A; Scase TJ
Vet Comp Oncol; 2008 Dec; 6(4):268-74. PubMed ID: 19178685
[TBL] [Abstract][Full Text] [Related]
5. PCNA and Ki67 proliferation markers as criteria for prediction of clinical behaviour of melanocytic tumours in cats and dogs.
Roels S; Tilmant K; Ducatelle R
J Comp Pathol; 1999 Jul; 121(1):13-24. PubMed ID: 10373290
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs.
Abadie JJ; Amardeilh MA; Delverdier ME
J Am Vet Med Assoc; 1999 Dec; 215(11):1629-34. PubMed ID: 14567425
[TBL] [Abstract][Full Text] [Related]
7. The value of immunohistochemical expression of BAX in formulating a prognosis for canine cutaneous mast cell tumours.
Strefezzi Rde F; Kleeb SR; Xavier JG; Fukumasu H; Catão-Dias JL
J Comp Pathol; 2012 May; 146(4):314-9. PubMed ID: 21899858
[TBL] [Abstract][Full Text] [Related]
8. Proliferation indices in spontaneous canine lung cancer: proliferating cell nuclear antigen (PCNA), Ki-67 (MIB1) and mitotic counts.
Griffey SM; Kraegel SA; Madewell BR
J Comp Pathol; 1999 May; 120(4):321-32. PubMed ID: 10208729
[TBL] [Abstract][Full Text] [Related]
9. Proliferating cell nuclear antigen (PCNA) expression as a prognostic indicator for renal cell carcinoma: comparison with tumour grade, mitotic index, and silver-staining nucleolar organizer region numbers.
Delahunt B; Bethwaite PB; Nacey JN; Ribas JL
J Pathol; 1993 Aug; 170(4):471-7. PubMed ID: 8105046
[TBL] [Abstract][Full Text] [Related]
10. An immunohistochemical study of vitamin D receptor expression in canine cutaneous mast cell tumours.
Russell DS; Rassnick KM; Erb HN; Vaughan MM; McDonough SP
J Comp Pathol; 2010; 143(2-3):223-6. PubMed ID: 20334872
[TBL] [Abstract][Full Text] [Related]
11. CD117 immunoexpression in canine mast cell tumours: correlations with pathological variables and proliferation markers.
Gil da Costa RM; Matos E; Rema A; Lopes C; Pires MA; Gärtner F
BMC Vet Res; 2007 Aug; 3():19. PubMed ID: 17711582
[TBL] [Abstract][Full Text] [Related]
12. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours.
Kiupel M; Webster JD; Miller RA; Kaneene JB
J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):280-6. PubMed ID: 16050909
[TBL] [Abstract][Full Text] [Related]
13. Assessment of proliferative activity in Wilms' tumour.
Delahunt B; Farrant GJ; Bethwaite PB; Nacey JN; Lewis ME
Anal Cell Pathol; 1994 Aug; 7(2):127-38. PubMed ID: 7993823
[TBL] [Abstract][Full Text] [Related]
14. Expression of Ki67, BCL-2, and COX-2 in canine cutaneous mast cell tumors: association with grading and prognosis.
Vascellari M; Giantin M; Capello K; Carminato A; Morello EM; Vercelli A; Granato A; Buracco P; Dacasto M; Mutinelli F
Vet Pathol; 2013 Jan; 50(1):110-21. PubMed ID: 22673539
[TBL] [Abstract][Full Text] [Related]
15. All subunits of the interleukin-2 receptor are expressed by canine cutaneous mast cell tumours.
Meyer A; Gruber AD; Klopfleisch R
J Comp Pathol; 2013 Jul; 149(1):19-29. PubMed ID: 23276382
[TBL] [Abstract][Full Text] [Related]
16. PCNA-LII, Ki-67 immunostaining, p53 activity and histopathological variables in predicting the clinical outcome in patients with parathyroid carcinoma.
Lumachi F; Ermani M; Marino F; Iacobone M; Baldessin M; Cappuzzo G; Zanella S; Favia G
Anticancer Res; 2006; 26(2A):1305-8. PubMed ID: 16619538
[TBL] [Abstract][Full Text] [Related]
17. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
Ioachim E
Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
[TBL] [Abstract][Full Text] [Related]
18. Recurrence rates and clinical outcome for dogs with grade II mast cell tumours with a low AgNOR count and Ki67 index treated with surgery alone.
Smith J; Kiupel M; Farrelly J; Cohen R; Olmsted G; Kirpensteijn J; Brocks B; Post G
Vet Comp Oncol; 2017 Mar; 15(1):36-45. PubMed ID: 25643820
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Ki67, Bax, Bcl-2 and KIT in canine cutaneous mast cell tumours and their relationship with histopathology and prognosis.
Aytemiz Danyer I; Gürel A
Acta Vet Hung; 2024 Jan; 71(3-4):183-192. PubMed ID: 38112689
[TBL] [Abstract][Full Text] [Related]
20. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors.
Kiupel M; Webster JD; Kaneene JB; Miller R; Yuzbasiyan-Gurkan V
Vet Pathol; 2004 Jul; 41(4):371-7. PubMed ID: 15232137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
